References
- Hill SL, Najafi J, Dunn M, et al. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Clin Toxicol. 2016;54:638–643.
- Seywright A, Torrance HJ, Wylie FM, et al. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. Clin Toxicol (Phila). 2016;54:632–637.
- Westin AA, Frost J, Brede WR, et al. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol. 2016;40:86–87.
- Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int. 2016;261:e5–e10.
- Rook W, Ford L, Vale A. Four analytically confirmed cases of use of third-generation synthetic cannabinoid receptor agonists incorporating an adamantyl group. Clin Toxicol. 2016;54:533–534.
- Ford LT, Berg JD. Analysis of legal high materials by UPLC-MS/TOF as part of a toxicology vigilance system. What are the most popular novel psychoactive substances in the UK? Ann Clin Biochem. 2016. [Epub ahead of print]. doi: 10.1177/0004563216651646.